BioElectronics Corp. A Sub-Penny Opportunity in Health Care Industry Analyst Report
NEW YORK, May 12, 2014 /PRNewswire/ -- BioElectronics Corp. (OTCBB: BIEL) One-third of the world's population suffers from chronic pain and many go untreated due to the lack of efficacious therapy, the cost, and the dangerous side effects of drug therapy. Chronic pain is pervasive throughout the world. Pain affects more than 100 million Americans, which is more than diabetes, heart disease and cancer, combined.
BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, anti-inflammatory devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses.
The underlying concept of the BIEL product line is to replace the short duration, high power treatments which can only be obtained in the clinic by a trained professional, with an easy to use, self-administered, very low power device that can be used 24 hours per day.
A full report on BIEL that includes risk factors, industry review, financial position, potential revenues, and review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link:
http://bit.ly/BIEL-AnalystReport
Copy and paste to browser may be required.
FORWARD-LOOKING DISCLAIMER
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Mark Bonacci, Analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
A full disclaimer can be found by viewing the full analyst report.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected]. For any urgent concerns or inquiries please contact us at [email protected].
Contact: [email protected]
810-715-9800
SOURCE BioElectronics Corp.
Share this article